ArticleJournal of nanobiotechnology2025
Structurally and functionally optimized silk fibroin-alginate-based biomimetic scaffolds reinforced with nanobioceramics for bone tissue engineering applications.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
- High-Performance Prevascularized SHED-Laden rGO@Hydrogel Achieves Optimized Diabetic Bone Defect Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hierarchical biomimetic scaffold with directional guidance and photothermal properties for the repair of critical-sized bone defects.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
In this study, we prepared chemically crosslinked silk fibroin (SF) and sodium alginate (Alg) biomimetic scaffolds reinforced with bioceramic nanohydroxyapatite (nHAp) for bone tissue engineering (BTE) applications. The pore sizes of these scaffolds were effectively controlled by varying the composition of the SF/nHAp/Alg biocomposites. The scaffold prepared with a 40:20:40 SF: nHAp: Alg ratio exhibited excellent swelling properties, reaching over 1700% within 70 min. In vitro degradation studies demonstrated that these biomimetic scaffolds exhibited controlled degradation, taking over 30 days to achieve 50% degradation. The scaffolds also showed good mechanical properties; they maintained structural integrity and did not break, even under a load approximately 800 times their own weight. Additionally, scaffolds loaded with synthetic peptide salmon calcitonin effectively controlled initial burst release and enabled sustained therapeutics delivery for up to two weeks. The biocompatibility of the scaffolds was evaluated using in vitro cell viability and hemolysis assays, which revealed good safety for human dermal fibroblast cells and negligible toxicity to rabbit red blood cells. Importantly, the scaffolds promoted cell proliferation and alkaline phosphatase secretion in human bone marrow stem cells. Histological and immunological analyses in a scaffold-implanted mouse model have demonstrated biocompatibility, supporting osteoclastic resorption and osteoblastic mineralization by downregulating RANKL. Furthermore, the chick chorioallantoic membrane assay showed the excellent angiogenic properties of the scaffold. These results suggest that the bioceramic-reinforced SF/Alg biomimetic scaffold has significant potential for use in BTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.